The recent Global Burden of Disease Study ranks a wide variety of cancers very highly in the leading causes of disability adjusted life years.

The predicted increases will place an unsupportable burden on the health care systems of these regions and will add to the cost burden in developed countries. More than 70% of these new cases will originate in Africa, Asia, and Central and South America and 70% of the world's cancer deaths will also occur in these regions. The number of new cancer cases will rise to 22 million within the next two decades. The CBIS Brand is currently being sold in multiple locations in California that are State licensed public and private cannabis dispensaries.Ĭancer is one of the leading causes of death worldwide and accounts for a large proportion of disability. The Company has increased its product releases through the Cannabis Science Research Foundation (CSRF) Ĭannabis Science has successfully released its first group of cannabinoids in California for test marketing and the positive results have been assessed as indicators to ramp up distribution and continue adding products, including pills, extracts, and creams, hiring of additional representatives and additional locations for a much larger products release. Dabney, President & CEO, Co-Founder Cannabis Science Inc., and the Cannabis Science Research Foundation. In addition, the PAC will become a critical tool in our drug development cycle,' stated Mr. Our patient-centered outcomes program, the Patient Access Center (PAC), will use extensive feedback from patients to inform our drug development efforts. Cancer is just one of our major targets, and building from our previous success, we are ramping up production to start fulfilling that demand. As we already know, affected people are looking for cannabinoid treatments for all types of acute and chronic illnesses. 'Our previous success with self-medicated patient usage is a great building block for us as our increasing requests for new products from self-medicating patients and dispensaries indicate. Cannabis Science is highly motivated to accelerate the pace of its cancer drug development studies and is ramping up its new products distribution to the California market immediately through additional product releases and additional licensing deals in each state-by-state regulated market and its formal FDA initiatives. The Company is focused on persuading governments and individuals across the world to expand their preventive and therapeutic actions against Cancer and other critical ailments. Company specializing in cannabis-based pharmaceutical development, is ramping up its formal and informal Cancer studies in response to the National Cancer Institute initiatives to help save millions of preventable deaths each year by raising its Cancer Studies awareness and education about cancer. LOS ANGELES, CA-(Marketwired - Sep 28, 2015) - Cannabis Science, Inc.

Abcd stock pattern